Lola McEvoy MP: written questions

4 Jul 2026–16 Oct 2026 · year in progress

How these years work

Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.

Read what this MP said, asked and contributed in Parliament.

3 published records · newest first.

Written questions

Continuing Care: FinanceDepartment of Health and Social CareTabled 28 Aug 2026AnsweredUIN 22172More
Question: To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of (a) making it easier for people with degenerative diseases to obtain NHS Continuing Healthcare (CHC) funding and (b) removing the requirement
Answer: The Department works with partners, including NHS England, external organisations and people with lived experience, to seek feedback on NHS Continuing Healthcare policy and implementation. This includes seeking feedback on how people with degenerative dis...
Answered 14 Sept 2026
Original Parliament record
ClozapineDepartment of Health and Social CareTabled 13 Jul 2026AnsweredUIN 18199More
Question: To ask the Secretary of State for Health and Social Care, what steps the MHRA intends to take to consider patient and bereaved family lived experience as part of its current scientific review of Clozapine; and whether he is taking steps to ensure that liv
Answer: The Medicines and Healthcare products Regulatory Agency (MHRA) confirms that in June 2026, the Neurology, Pain and Psychiatry Expert Advisory Group (NPPEAG) considered an assessment of clozapine drug level monitoring. The NPPEAG provided advice about the ...
Answered 20 Jul 2026
Original Parliament record
Clozapine: Side EffectsDepartment of Health and Social CareTabled 13 Jul 2026AnsweredUIN 18198More
Question: To ask the Secretary of State for Health and Social Care, whether the Yellow Card adverse drug reaction reference GB-MHRA-MED-202605220730230940-NSQYR (linked to case file CEC 256289) is being actively reviewed by the clinical assessors of the Neurology,
Answer: The Medicines and Healthcare products Regulatory Agency (MHRA) confirms that in June 2026, the Neurology, Pain and Psychiatry Expert Advisory Group (NPPEAG) considered an assessment of clozapine drug level monitoring. The NPPEAG provided advice about the ...
Answered 20 Jul 2026
Original Parliament record

Explore activity by topic or department

Written questions by answering department

4 Jul 2026–16 Oct 2026. One record per UIN and tabled date; the named department is not a measure of answer quality.

View as list

What this shows and doesn't show

4 Jul 2026–16 Oct 2026. One record per UIN and tabled date; the named department is not a measure of answer quality. Published records do not measure effort or effectiveness. Methodology.

Department or topic	Published records
Department for Business, Innovation, Science and Trade	1
Department for Education	1
Department for Energy Security and Net Zero	1
Department for Transport	1
Department for Work and Pensions	1
Department of Health and Social Care	3
Ministry of Defence	2
Ministry of Justice	2

Published records only — not a full account of an MP’s work. How we work →